Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Mikhail V. Blagosklonny has then
Relocated to the United States, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diverse biomedical themes, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer on a clinical phase I/II
Trial paper.
 
After authoring seven papers during a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published dozens of experimental research articles and theoretical articles as lead
Author. The abovementioned sole-author publications
Discussed two important topics.
The first of those mentioned selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Exploiting their resistance. The results and underlying
Concept were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the publication was
Named, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author works
Is a research method to come up with knowledge via
Uniting a few facts together from seemingly irrelevant fields.
This results in new notions containing testable predictions, which in
Turn can be “tested” via analyzing the literature further. Likewise, the
Concept was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Noticeable outcome discovered by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others don' t even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Inhibiting body aging — in other words, “preventing cancer
By staying young. ” His laboratory closely collaborated with
Andrei Gudkov’s and conducted research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Medications besides rapamycin. The cell culture studies were
Complemented by studies in mice, including several models such as
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Mikhail Blagosklonny has also published extensively on the prevention of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Prolongation and cancer cure in mice, and combinations of anti-
Aging medications to be used in humans. A
Rapamycin-based combination of seven clinically available medicines has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.